Princeton, NJ, November 6, 2023 (Reuters) -- Bristol Myers Squibb (BMY.N) acquires an experimental therapy to treat a type of blood cancer for an upfront payment of $100 million and a total value of up to $180 million from Orum Therapeutics' a privately held company. The therapy has early stage study clearance from the FDA.
Read full article here.
Rahway, NJ & Cambridge, MA, November 21, 2023 (Business Wire) -- Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. declare a definitive agr
Zürich, Switzerland, November 16, 2023 (Business Wire) -- Memo Therapeutics AG (“MTx”), a late-stage biotech firm advancing top-tier therapeutic antibodies, discloses the appointment of Erik van den
Marlborough, MA, November 17, 2023 (PRNewswire) -- Boston Scientific Corporation (NYSE: BSX) announces the completion of its acquisition of Relievant Medsystems Inc., the sole provider of the FDA-cl
